Measuring the Symptom Burden of Lung Cancer: The Validity and Utility of the Lung Cancer Module of the M. D. Anderson Symptom Inventory

Abstract

We conducted a study to establish the psychometric properties of a module of the M. D. Anderson Symptom Inventory (MDASI) developed specifically for patients with lung cancer (MDASI-LC). The MDASI measures 13 common “core” symptoms of cancer and its treatment. The MDASI-LC includes the 13 core MDASI symptom items and three lung cancer-specific items: coughing, constipation, and sore throat. MDASI-LC items were administered to three cohorts of patients with lung cancer undergoing either chemotherapy or chemoradiotherapy. Known-group validity and criterion (concurrent) validity of the MDASI-LC were evaluated using the Eastern Cooperative Oncology Group performance status and the 12-item Short-Form Health Survey. The internal consistency and test-retest reliability of the module were adequate, with Cronbach coefficient α-values of 0.83 or higher for all module items and subscales. The sensitivity of the MDASI-LC to changes in patient performance status (disease progression) and to continuing cancer treatment (effects of treatment) was established. Cognitive debriefing of a subset of participants provided evidence for content validity and indicated that the MDASI core items and three additional lung cancerspecific items were clear, relevant to patients, and easy to understand; only two patients suggested additional symptom items. As expected, the item “sore throat” was sensitive only for patients receiving chemoradiotherapy. The MDASI-LC is a valid, reliable, and sensitive symptom-assessment instrument whose use can enhance clinical studies of symptom status in patients with lung cancer and epidemiological and prevalence studies of symptom severity across various cancer types.

Linking Fatigue Measures on a Common Reporting Metric

“…Defined as a subjective sensation of overwhelming and debilitating weakness, lack of energy, or tiredness, fatigue affects millions of people with various chronic conditions such as systemic lupus erythematosus, (1) rheumatoid arthritis,(2) cancer, (3) and Parkinson's disease. (4) Given its high prevalence, and the impact it has on quality of life, it is important to assess fatigue using standard, reproducible instrumentation in order to inform clinical practice and future research.…”

Measuring the symptom burden associated with the treatment of chronic myeloid leukemia

“…Additional symptom items can be appended to the 13 symptom and 6 interference items of the core MDASI to form disease-or treatment-specific modules. [17][18][19][20][21][22][23] The number of additional module-specific symptom items is minimized to keep the module concise and to facilitate repeated measurement.…”

Levels of Symptom Burden During Chemotherapy for Advanced Lung Cancer: Differences Between Public Hospitals and a Tertiary Cancer Center

“…Previous studies indicate that poorer ECOG PS, 9,14 a history of prior treatment, and advanced disease 10 can be associated with higher symptom severity. We sought to lessen the bias of potential site differences relative to these known factors by conducting a logistic regression to calculate propensity scores for cancer stage, ECOG PS, and prior treatment.…”

“…One lung cancer-specific symptom, coughing, was added to the MDASI for this study. 10 Each symptom is rated on an 11-point scale, with 0 being "not present" and 10 being "as bad as you can imagine." Previous research has shown that MDASI symptom ratings collected from various cultural and language groups can be interpreted in a similar way in oncology practice and clinical research, with culture and language having only modest impacts on symptom ratings.…”